Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from InMed Pharmaceuticals ( (INM) ).
On March 9, 2026, InMed outlined its 2026 pharmaceutical development outlook, highlighting significant 2025 preclinical progress for lead Alzheimer’s candidate INM-901, including reduced inflammatory and neurodegenerative biomarkers, evidence of neuroprotection and neurite outgrowth, behavioral improvements, and favorable oral bioavailability, alongside advances in formulation, manufacturing scale-up and regulatory preparation. The company plans a pre-IND meeting with the U.S. FDA for INM-901 in Q3 2026 and continued IND-enabling studies to support a targeted Phase 1 trial initiation in 2027, while its INM-089 dry age-related macular degeneration program has generated supportive preclinical and manufacturing data ahead of a planned Q4 2026 pre-IND meeting, underscoring InMed’s bid to strengthen its position in neuroinflammation-focused and ocular therapeutics and to create longer-term value for shareholders.
MainPoint1: InMed reported strong 2025 preclinical gains for INM-901, showing anti-neuroinflammatory effects, neuroprotection, behavioral benefits and oral bioavailability, while advancing formulation, manufacturing and regulatory groundwork.
MainPoint2: The company’s 2026 plan centers on FDA pre-IND meetings and IND-enabling work for INM-901 and INM-089, aiming to launch a Phase 1 Alzheimer’s trial in 2027 and reinforce its neuroscience and ocular disease pipeline.
The most recent analyst rating on (INM) stock is a Hold with a $0.84 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
The score is primarily constrained by weak financial quality (large ongoing losses and persistent cash burn despite improving revenue and low debt) and bearish technical trend signals (trading below major moving averages with negative MACD). Corporate events add incremental risk due to regulatory-driven BayMedica wind-down and potential financing/dilution considerations, while valuation inputs are not informative enough to provide support.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a Vancouver-based pharmaceutical company developing a pipeline of proprietary, disease-modifying small molecule drug candidates that target CB1/CB2 receptors. Its programs span Alzheimer’s disease, ocular disorders such as dry age-related macular degeneration, and dermatological indications, positioning the company in niche neurology and specialty disease markets.
Average Trading Volume: 103,281
Technical Sentiment Signal: Sell
Current Market Cap: $2.69M
Find detailed analytics on INM stock on TipRanks’ Stock Analysis page.